Objective: To determine whether healthy males who consumed increased amounts of dietary stearic acid compared with increased dietary palmitic acid through the consumption of commercially available foods, exhibited any changes in plasma lipids, platelet aggregation or platelet activation status. Design: A randomised cross-over dietary intervention. Subjects and interventions: Nine free-living healthy males consumed two experimental diets (stearic acid enriched, diet S, and palmitic acid enriched, diet P) for 3 weeks in a randomised cross-over design separated by a 3 week washout phase. The diets consisted of $ 30% of energy as fat (30% of which was derived from the treatment diets) providing $ 13 g=day as stearic acid and 17 g=day as palmitic acid on diet S and $ 7 g=day as stearic acid and 22 g=day as palmitic acid on diet P. The dietary ratio of stearic to palmitic acids was 0.76 on diet S compared with 0.31 on diet P. Blood samples were collected on days 0 and 21 of each dietary period. Results: LDL cholesterol levels and platelet aggregation response to the agonist ADP were significantly decreased (P < 0.025) in subjects on diet S compared with day 0. Apart from that, there were no significant changes in plasma lipids, platelet aggregation, mean platelet volume and platelet reactivity between diets. There were no significant changes in stearic or palmitic acid levels in plasma phospholipid or triacylglycerol. There was a significant difference in palmitic acid levels in platelet phospholipids between the two diets. Conclusions: Use of commonly available foods led to a 27% increase in stearic acid (diet S) and a 19% increase in palmitic acid (diet P), on diets S and P respectively, and no significant differences between the two diets in plasma lipoprotein concentrations, platelet aggregation or platelet activation status.
Introduction
The relationship between dietary fatty acids and blood cholesterol levels was reported in the late 1950s when Keys et al (1957) found that saturated fatty acids (SFAs) from 12 to 18 carbon atoms were potent cholesterol raising agents. Subsequently, it was found that stearic acid was neutral in relation to plasma cholesterol changes (Hegsted et al, 1965; Keys et al, 1965) . There are now a number of dietary studies which support the unique cholesterol-neutral properties of stearic acid (Kris-Etherton and Mustad, 1994; Tholstrup et al, 1994; Bonanome & Grundy, 1988) , however the mechanisms behind this effect are not yet clear (Bonanome & Grundy, 1989; Kris-Etherton et al, 1993; Emken, 1994; Tholstrup et al, 1994; Dougherty et al, 1995; Rhee et al, 1997; Salter et al, 1998) .
The risk of coronary events is not solely dependent on plasma cholesterol levels. It is now increasingly accepted that activated platelets play a central role in the development of cardiovascular disease (CVD) and its associated complications. Their contribution to CVD has been supported by findings that patients with various forms of CVD have been found to have increased levels of platelet activation (Bath & Butterworth, 1996; Cahill et al, 1996; Murakami et al, 1996; Schultheiss et al, 1994) . In addition to its neutral cholesterol effects, some studies report that stearic acid-enriched diets are associated with reduced platelet aggregation. Recent studies involving SFAs have focused attention on assessing changes in platelet activity as a means of better understanding the relationship between SFA and thrombosis. Platelets normally circulate in a quiescent disc-shaped state and as they activate they undergo a disc-to-sphere transformation with the development of pseudopodia, causing a subsequent increase in size (Allen et al, 1979) . The increase in size or volume after the development of pseudopodia as measured by electronic impedance, is one of the simplest methods available for assessing platelet activation. However, electronic impedance measurement of mean platelet volume (MPV) is not a measure of true volume, it is a measure of size and shape (Schoene, 1997) . Three studies have shown a decrease in MPV following increased intakes of stearic acid which suggests this corresponds to less active platelets (Schoene et al, 1992; Waring et al, 1998; Kelly et al, 2001) . Platelet aggregation is a well-established method used for the assessment of platelet function in response to agonists. To date, measurement of in vitro platelet aggregation has been the only means of confirming that the reduction in MPV associated with diets high in stearic acid corresponds to a reduction in platelet activity. However, more sensitive tests are required to determine if this decrease in MPV is functionally related to decreases in platelet activation.
Upon activation, platelets undergo changes which alter antigen expression on the platelet surface and lead to platelet adhesion and aggregation. The expression of platelet surface antigens involved in platelet activation can be assessed by flow cytometry. Using this technique it has been demonstrated that there are increased levels of platelet activity in patients with CVD (Cahill et al, 1996; Murakami et al, 1996; Schultheiss et al, 1994; Furman et al, 1998) . Whole blood techniques for flow cytometry which avoid sample preparation induced changes have been developed to obtain information on platelet activation (Goodall and Macey, 1994; Wilkinson, 1996) , however, only recently has this technique been applied to dietary intervention studies (Rein et al, 2000a) .
The aim of this study was to determine the effect of a stearic acid enriched diet on thrombotic risk factors associated with changes in platelet morphology and activity. A comparison diet similarly enriched in palmitic acid was included as a control group in this cross-over study. The hypothesis was that the diet enriched in stearic acid would show a reduced platelet activation status.
Methods

Subjects
Nine free-living healthy males were recruited following advertisement of the study throughout RMIT University. Subjects were aged 39 AE 10 y (mean AE s.d.), of body mass index (BMI) 25 AE 2.5 kg=m 2 . Subjects had no known metabolic, endocrine or haematological diseases, were non-smokers, not on any form of medication and had a moderate physical activity level. Subjects were advised not to take any form of non-steroidal anti-inflammatory drugs 14 days prior to commencement and during the study. Subjects were counselled to maintain their usual intake of alcohol and to abstain from consuming alcohol 24 h prior to blood sampling. All subjects were required to give written consent to participate in the study and were free to withdraw at any time. The study protocol was approved by the Human Research Ethics Committee of Royal Melbourne Institute of Technology University (approval number 25=98).
Experimental design
The study was a single blinded randomised crossover trial of 9 weeks duration. The dietary intervention consisted of subjects consuming two diets, one high in stearic acid (diet S) and the other high in palmitic acid (diet P), for 3 weeks with a 3 week washout (habitual diet) period between the two periods. During the two intervention phases, the percentage energy derived from fat, carbohydrate and protein and the fatty acid composition was kept constant for each individual, based on habitual food records. For diet S, 96 g of milk chocolate was provided each day, whereas for diet P, combinations of snack foods high in palmitic acid and low in stearic acid such as potato crisps, shortbread biscuits and muesli bars were provided for the subjects to consume daily. The palmitic acid content of the palmitic snack combinations was approximately equal to the total palmitic plus stearic acid content of 96 g milk chocolate. Subjects were counselled prior to commencement of the first intervention period, with advice being provided on which foods to avoid during the two diet periods in order to allow the consumption of high palmitic or high stearic acid snacks. Foods that were excluded from the diet were high saturated fat containing foods including regular fat dairy products, pastries and cakes etc with advice being provided on suitable low-fat alternatives. Subjects were given training in recording their food intakes and completed a 7 day weighed food record (WFR) of their habitual diet prior to the study. Dietary intakes during both the intervention and washout periods were assessed using similar WFRs. Dietary composition was determined by a dietitian using Diet 1 (Version 4, NUTTAB 95, Xyris Software Pty Ltd, Queensland, Australia) based on Composition of Foods, Australia (Australian & New Zealand Food Authority, 1995) . The database was modified by the inclusion of fatty acid data, for a wider range of foods, for C12:0 to C18:0 (lauric, myristic, palmitic and stearic acids), palmitoleic acid (C16:ln-7) and oleic acid (C18:ln-9), linoleic Stearic and palmitic acid-enriched diets FD Kelly et al acid (18:2n-6) and alpha linolenic acid (18:3n-3) obtained from Dr M James, University of Adelaide.
Blood sampling and preparation
Fasting venous blood samples ( ! 10 h) were taken from the subjects before the commencement (day 0), and at the end (day 21) of each study period by a qualified nurse at the RMIT University Health Service using standard vacutainer collection tubes. Blood for platelet fatty acid analysis, blood lipid analysis and blood cell counts was collected into vacutainers containing tri-potassium EDTA (1.8 mg=ml; Greiner Labortechnik, Austria). Blood for whole blood platelet aggregation and flow cytometry was collected into vacutainers containing sodium citrate (3.8%; Greiner Labortechnik). EDTA and citrated plasma was obtained from blood spun at 3000 g at 15 C for 10 min. Plasma fatty acids, total cholesterol, high density lipoprotein cholesterol and triglycerides were determined from EDTA plasma stored at 720 C.
Physiological measurements
Subjects had their weight, height and BMI (kg=m 2 ) determined, and percentage body fat measured using a bioimpedence fat analyser=scale (TBF-501 Tanita Corporation, IL, USA). Systolic and diastolic blood pressures and pulse were also measured at each appointment on a Lumiscope Digital Auto Inflate Blood Pressure Monitor (Lumiscope Company Inc., NJ, USA).
Plasma lipid and lipoprotein lipids
Total cholesterol (TC) and triacylglycerol (TAG) concentrations in plasma were determined with a centrifugal autoanalyser (Hitachi Autoanalyser System 705, Japan) using commercially available enzymatic kits, CHOD-PAP and GPO-PAP for TC and TAG, respectively (Boehringer Mannheim, Germany). High-density lipoprotein cholesterol (HDL-C) was measured after all other plasma lipoproteins were precipitated with polyethylene glycol 6000 (PEG-6000, BDH Chemicals, Kilsyth, Victoria, Australia). Low-density lipoprotein cholesterol (LDL-C) was calculated from the values obtained for TC, HDL-C and TAG for each subject using the Friedewald formula as developed by DeLong et al (1986) .
Fatty acids in snack foods, chocolate, platelets and plasma The lipids of the palmitic snacks, chocolate, platelets and plasma were extracted using an adapted Folch chloroformmethanol extraction method (Sinclair et al, 1987) . Fatty acid methyl esters for each sample were prepared and determined by gas-liquid chromatography as previously described (Sinclair et al, 1987) .
Blood cell count
A full blood cell count (including platelet count and MPV) was performed 15 min post-collection on an automated haematological analyser (Coulter Counter STKR, Coulter Electronics Inc., FL, USA).
Whole blood platelet aggregation
Whole blood platelet aggregation measured by impedance was performed using a dual channel whole blood aggregometer (Chrono-Log Corporation, Philadelphia, USA) equipped with MacLab Software Version 3.1 for data analysis. Citrated blood samples were diluted 1:1 with physiological saline and warmed to 37 C. Agonists used were ADP 8 mM, collagen 2 mg=ml, arachidonic acid 1 mM and thrombin 0.07 U=ml (Chrono-Log Corporation, Philadelphia, USA). Each agonist was added to a single sample and aggregation was recorded for 6 min. Results were expressed as rate of aggregation as O=s (slope) as reported by Ingerman-Wojenski and Silver (1984) .
Flow cytometry
Monoclonal antibodies (MoAb). Anti-CD61 (Becton= Dickinson, San Jose, CA, USA) conjugated to fluorescein isothiocyanate was used to identify the GP IIIa portion of the GP IIb=IIIa complex on the platelet surface. Anti-CD41 (Immunotech, Marseille Cedex, France) conjugated to Phycoerythrin (PE) was used to identify GP IIb. The expression of CD41 on the platelet membrane is up-regulated on activated platelets by redistribution from a-granules and the open canaliculi system. Anti-CD62P (Immunotech, Marseille Cedex, France) conjugated to PE was used to identify the agranule protein, P-selectin. CD62P is a late activation marker, which is expressed on the platelet surface following granule secretion. All antibodies were used at the optimum concentration appropriate for the sample platelet count as recommended by the manufacturer. An IgG1-PE MoAb (Becton=Dickinson, San Jose, CA, USA) was used as an isotype control for anti-CD62P and the protein concentration of the isotype control was matched to the MoAb.
Sample preparation. Samples were prepared using a modified flow cytometric procedure (Michelson et al, 1991) . Within 10 min of blood collection, samples were diluted 1=10 in filtered (0.22 mM filter) modified Tyrode's buffer (137 mmol=l NaCl, 2.8 mmol=l KCI, 1 mmol=l MgCl 2 , 12 mmol=l NaHCO 3 , 0.4 mmol=l Na 2 HPO 4 , 10 mmol=l HEPES, 5.5 mmol=l glucose, 0.35% bovine serum albumin, final pH 7.4; Wilkinson, 1996) and activated for 5 min at 22 C undisturbed with 1 or 3 mM ADP or 0.002 U=ml thrombin. GPRP (glycyl-L-prolyl-L-arginyl-L-proline) was added (Sigma Aldrich Pty Ltd, NSW, Australia) to thrombin activated samples at a final concentration of 2.5 mmol=l. Preliminary experiments showed that a 1=10 dilution of samples minimised platelet -platelet and platelet -leucocyte Stearic and palmitic acid-enriched diets FD Kelly et al aggregates. Fifty microlitres of the appropriate diluted activated sample was added to a specified combination of MoAbs and incubated for 15 min at 22 C. Samples were fixed with 70 ml of 2% paraformaldehyde for 15 min at 22 C and stopped by the addition of 500 ml of modified Tyrode's buffer. Samples were stored in the dark at room temperature until analysis that same day.
Sample analysis was performed on an EPICS Elite flow cytometer (Coulter Electronics, Hialeah, FL, USA) equipped with a 15 mW argon laser (488 nm) with band pass filters for FITC (525 nm) and PE (575 nm) conjugated MoAbs. Detection of fluorescence intensity was validated and standardised using Flow-Set COULTER fluorospheres (Coulter). Platelets were initially identified on the basis of their forward angle light scatter and their fluorescence with either anti-CD61 or anti-CD41. A population of single platelets was further identified on the basis of their forward and side angle light scatter. Platelet -platelet and platelet -leucocyte aggregates were excluded by their higher forward and side angle light scatter. A total of at least 20 000 platelet events were collected for each analysis. Fluorescent thresholds were set for the analysis of CD62P expression using a negative control of the isotype for the MoAb. The percentage of cells expressing the activation marker CD62P was determined. Up-regulation of CD41 on platelets was determined by measuring the mean fluorescent intensity (MFI).
Statistics
Statistical analysis was performed using Statistical Packages for Social Scientists (SPSS version 9.0, 1998, Chicago, IL, USA). Comparisons between the dietary groups involved a three-way repeated measures analysis of variance using a general linear model (GLM), where diet type (palmitic or stearic rich) and time were within-subjects factors and dietary order was the between subject factor (P < 0.05 was regarded as significant). Comparisons within individual diets (between days 0 and 21) were conducted on parameters where a significant time Â treatment or time effect was observed using paired t-tests and Bonferroni correction (P < 0.025 was regarded as significant).
Results
All subjects stayed within 2 kg of their initial body weights throughout the dietary phases of the study. There were no significant changes in BMI, waist-to-hip ratio, or blood pressure between the two dietary interventions or during either dietary period relative to baseline.
The fatty acid contents per 100 g of the chocolate and snacks provided are presented in Table 1 . The mean nutrient intakes for all subjects at baseline and during the two dietary phases are presented in Table 2 . While the intention was that the diets would differ only in the amount of stearic and palmitic acids, there were also significant differences between diets (P < 0.05) in the proportion of monounsaturated fatty acid (MUFA; as a percentage of total energy, %TE) and dietary fibre. There were significant decreases (P < 0.025) in the amount of protein (%TE), fat and sodium and a significant increase in the carbohydrate intake (%TE) consumed on diet S compared with the usual diet. There was a significant increase in carbohydrate intake (P < 0.025) and a decrease in SFA (%TE) intake (P < 0.025) during diet P compared with the usual diet.
Based on the subjects' WFR intakes and the Tables of Food Composition (Australia & New Zealand Food Authority, 1995) , there were significant differences in the intakes of palmitic, stearic and lauric acids on diet S compared with diet P (P < 0.05; Table 3 ). On diet S, there was a 2.7 g=day increase in stearic acid (P < 0.025) and decreases of 2.0 and 1.7 g=day in myristic and lauric acid intakes (P < 0.025), respectively, compared with the subjects' usual diets. On diet P, there was a 3.5 g=day increase in palmitic acid (P < 0.025) and decreases of 2.2 and 1.2 g=day in stearic and myristic acids, respectively (P < 0.025), compared with the subjects' usual diets. The total fat intake on diet S was significantly lower (P < 0.025) than the subjects' usual diet. There were three dietary parameters affected by diet order (whether the subjects started the study on diet P first or diet S first). The fat (%TE) fell in one of the two groups in diet P and fell in both groups in diet S. On diet P, the percentage energy from MUFA fell in the group starting on diet P and rose in the other group. The stearic acid intake fell in both groups on diet P but rose more in one group than the other on diet S.
There were no significant differences between diet S and P in any of the plasma lipoprotein lipids measured; however, there was a significant decrease in LDL-C (P < 0.025) on diet S Stearic and palmitic acid-enriched diets FD Kelly et al compared with baseline (Table 4 ). There were no significant changes in the MPV between the two diets, nor were there changes in any of the other full blood examination parameters measured (Table 5 ). There were no significant changes in the stearic, palmitic or oleic proportions in the plasma phospholipid between diets S and P; however there was a significant decrease (P < 0.025) in the myristic acid proportion in the plasma phospholipid on diet S compared with baseline (Table 6 ).
There was a significant difference (P < 0.05) in the change in stearic acid in the plasma TAG fraction on diet S compared with diet P (Table 7) and a significant increase (P < 0.025) in the proportion of oleic acid and 22:4n-6 in the plasma TAG on diet S relative to baseline.
There was a significant difference in the proportion of palmitic acid and oleic acid in the platelet phospholipid on diets S compared with diet P (P < 0.05; Table 8 ). Diet S resulted in a significantly decreased (P < 0.025) oleic acid level and diet P resulted in a significantly decreased (P < 0.025) C22:5n-3 level in platelet phospholipid compared with their respective baselines.
There were no significant differences in the rate of platelet aggregation between diets S and P; however the rate of platelet aggregation was significantly reduced Table 2 Daily nutrient intakes of subjects at baseline and during the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) Dietary intake during the study. *Significantly different from baseline within diet, P < 0.025 (paired t-test with Bonferroni correction), applied to parameters where a significant timeÂtreatment interaction or time effect was observed. Table 3 Daily fatty acid intakes of subjects at baseline and during the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) Dietary intake during the study. *Significantly different from baseline within diet, P < 0.025 (paired t-test with Bonferroni correction), applied to parameters where a significant timeÂtreatment interaction or time effect was observed.
Stearic and palmitic acid-enriched diets FD Kelly et al Table 4 Lipoprotein concentrations of subjects at baseline and the end of the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) Table 6 Fatty acid composition of plasma phospholipids (percentage fatty acid) of subjects at baseline and the end of the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) Stearic and palmitic acid-enriched diets FD Kelly et al (P < 0.025) in response to ADP on diet S compared with baseline (Table 9 ). There were no significant changes in the expression of CD62P in ADP and thrombin stimulated platelets between the two diets. Similarly, CD41 was not up-regulated in ADP stimulated platelets (Table 10) .
Discussion
In other studies investigating the effects of stearic acid on plasma lipids, platelet aggregation and platelet activation status, the level of stearic acid ranged from 7 to 58 g=day (Kwon et al, 1991; Tholstrup et al, 1994; Waring et al, 1998; Kelly et al, 2001 ) and was achieved using high intakes of chocolate (100 g=day) or specially formulated fats enriched in stearic acid. Our experience with such diets is that it leads to difficulties with compliance. The aim of the present study was to increase the stearic acid or palmitic acid content as high as possible using commercially available foods and having minimal effect on subject compliance.
Previous studies have demonstrated a decrease in MPV in subjects on stearic acid-enriched diets (Schoene et al, 1992; Waring et al, 1998; Kelly et al, 2001) ; however, in this study neither diet showed significant changes in MPV. There was, however, a trend for the MPV to decrease on diet S and increase on diet P. The MPV is regarded as an index of Table 8 Fatty acid composition of platelet phospholipids (percentage fatty acid) of subjects at baseline and the end of the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) P, level of significance; T, significant time effect, P < 0.05; TÂD, significantly different change in parameter between diets, P < 0.05 (timeÂtreatment interaction); GLM, repeated measures ANOVA. *Significantly different from baseline within diet, P < 0.025 (paired t-test with Bonferroni correction), applied to parameters where a significant timeÂtreatment interaction or time effect was observed. Table 7 Fatty acid composition of plasma triacylglycerol (percentage fatty acid) of subjects at baseline and the end of the 3 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) P, level of significance; T, significant time effect, P < 0.05; TÂD, significantly different change in parameter between diets, P < 0.05 (timeÂtreatment interaction); GLM, repeated measures ANOVA. *Significantly different from baseline within diet, P < 0.025 (paired t-test with Bonferroni correction), applied to parameters where a significant timeÂtreatment interaction or time effect was observed.
Stearic and palmitic acid-enriched diets FD Kelly et al platelet activation and a decreased MPV is thought to represent a shift in the platelet population towards smaller, less reactive platelets. This is important, as larger platelets are functionally more reactive and have been identified in a number of cardiovascular conditions (Bath & Butterworth, 1996; Cahill et al, 1996; Murakami et al, 1996; Schultheiss et al, 1994) . Platelets with lower MPV may therefore be less likely to contribute to thrombus formation. In the present study, the dietary stearic acid was increased by 3 g=day on diet S while in the other two studies it was increased by approximately 9 g=day (Waring et al, 1998) and 12 g=day (Kelly et al, 2001 ). There was no significant change in the stearic acid content of platelet phospholipid in this study compared with an 8 and 22% increase in the studies by Waring et al (1998) and Kelly et al (2001) , respectively, although the platelet phospholipid palmitic to stearic acid ratio decreased significantly on diet S (P < 0.05). In the present study, milk chocolate was used rather than dark chocolate to assist in subject dietary compliance. The stearic acid content of dark chocolate is only 1.2 g=100 g more than in milk chocolate. Since milk chocolate contains both palmitic and stearic acid at similar levels, it was difficult to substantially increase dietary stearic acid levels without also increasing the palmitic acid.
There were no significant changes observed in the surface antigen expression of platelets on either diet. It is thought that even small changes in platelet activation levels may be of biological significance as only a small number of platelets are required to begin the process of thrombus formation (Cahill et al, 1996) . One possibility for the absence of any change in the expression of platelet activation markers may be due to the markers used (CD41 and CD62P), which detect late activation. Secondly, the large inter-subject variation in activation marker expression in response to agonist stimulation may necessitate a larger sample size. Future studies may include the use of PAC1 to identify conformational changes in the fibrinogen receptor of the GP IIb=IIIa complex following platelet activation. PAC1 is an early marker of platelet activation occurring prior to aggregation and is not detected on resting platelets (Shattil et al, 1985) , and therefore may detect small changes in activation status in dietary interventions.
The mechanisms by which SFA might influence platelet function are not understood, although it is known that diets rich in these fatty acids can increase their level in platelet membrane phospholipid Waring et al, 1998; Kelly et al, 2001) . It has been suggested that SFA may exert an effect on the expression of activation dependent antigens on the platelet surface (Mutanen, 1997) . Since activation-related changes in platelet antigen expression are thought to involve signalling pathways across the platelet membrane, it is possible that alterations in the fatty acid Table 9 Agonist-induced whole blood platelet aggregation (O=s) in subjects at baseline and the end of the 3 week and stearic acid (diet S) and palmitic acid (diet P) intervention periods (n ¼ 9) Stearic and palmitic acid-enriched diets FD Kelly et al composition of platelet membrane phospholipid could influence surface antigen expression through changes in membrane order (fluidity) and the mobilisation of proteins to the membrane surface (Mutanen, 1997; Litman & Mitchell, 1996) . A significant decrease was found in the rate of ADPinduced platelet aggregation on diet S resulting from a moderate increase in stearic acid of 3.5 g per day, totalling 12.6 g per day. This finding supports data of studies by Kwon et al (1991) , Tholstrup et al (1994) and Waring et al (1998) , who demonstrated decreases in ADP-induced platelet aggregation with calculated dietary stearic acid intakes of 7.3 -9.2 g per day, 58 g per day and an increase of 9 g per day, respectively. Although there were no significant differences in platelet aggregation with an increase of palmitic acid intake of 3.5 g per day on diet P in the present study, it has been previously shown with a daily increase of 7 g palmitic acid totalling 22.5 g per day, increased collagen-, arachidonic acid-and ADP-induced aggregation reponses (Kelly et al, 2001) . The data reported by various authors on the effect of dietary stearic acid on platelet aggregation have been conflicting. It has been demonstrated that for a particular dietary fatty acid, the aggregatory response to the same agonist can give opposing results (Kwon et al, 1991; Turpeinen et al, 1998) , which may be due partly to the medium in which platelet aggregation has been studied. There is some debate among researchers as to whether in vitro platelet aggregation in whole blood or using platelet-rich plasma is more appropriate. Whole blood aggregation may represent more closely in vivo conditions since leucocytes and erythrocytes, which can down-regulate platelet reactivity and enhance platelet activation, respectively, are not excluded from the process of aggregation (Hornstra, 1989; Marcus & Safier, 1993) . Conflicting data may also arise from differences in dietary sources of stearic acid. For example, the nonsaponifiable components of fats and oils (sterols, polyphenols, tocopherols) vary and some of the effects ascribed to the stearic acid content of a particular dietary fat may be due to these other components. In this context, cocoa and chocolate contain potent polyphenol anti-oxidants which could influence platelet function (Adamson et al, 1999) ; thus, the effects of diets rich in chocolate on platelet function may be due to the anti-oxidants in the chocolate rather than, or in addition to, the stearic acid. This remains to be clarified.
The flow cytometry and platelet aggregation results obtained in this study do not appear to correlate well. The decrease in platelet aggregation seen on diet S was not mirrored by a decrease in the expression of activation dependent antigens on the platelet surface. There are several possible explanations for this finding. Firstly, these techniques measure platelet activation using different principles. Whole blood platelet aggregation is a functional assay, whereas flow cytometry is an immunologic assay. Flow cytometry measures a very specific event in the process of platelet activation and, by using different monoclonal antibodies, detects particular aspects of platelet activation. Platelet aggregation assays on the other hand do not measure platelet activation per se, but the entire cascade from platelet activation to the final aggregation of platelets to form a platelet plug (Mutanen, 1997) . Other investigators have also noted that platelet antigen expression does not necessarily correlate well with platelet aggregation response (Serebruany et al, 1998) .
LDL-C levels in the plasma were significantly decreased during diet S with a total dietary stearic acid intake of 12.6 g per day. This evidence of cholesterol lowering may be associated with a decrease in total dietary fat intake on diet S and the displacement of the cholesterolaemic saturated fatty acids (C14:0 and C16:0) by stearic acid. These results are consistent with data from Bonanome and Grundy (1988) , Tholstrup et al (1994) and Kelly et al (2001) , who demonstrated this decrease with greater calculated total dietary stearic acid intakes of 46 g, 58 g and 19.4 g per day, respectively. Tholstrup et al (1994) , Dougherty et al (1995) and Kelly et al (2001) have previously reported a significant decrease in HDL cholesterol concentrations on high stearic acid diets (58, 23.6 and 19.4 g per day, respectively) compared with baseline.
This study supports other studies which show that diets enriched in stearic acid do not contribute to an increase in classical CVD risk factors and can actually be associated with cholesterol lowering and reduced platelet aggregation. While there was only a modest increase of 3 g stearic acid per day from baseline, it has been shown that this increase is obtainable through commercially available foods (such as chocolate). Our data on a modified diet containing 27% more stearic acid than usual raises the possibility of using fats in the food supply enriched in stearic acid at the expense of palmitic and myristic acids or trans fatty acids, however, the sensory characteristics of stearic acid-enriched foods need to be investigated further.
